DOCSLIB.ORG

Comparative Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction in Diabetic Men: a Bayesian Netw

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

World Journal of Urology (2019) 37:1061–1074 https://doi.org/10.1007/s00345-018-2583-1 REVIEW Comparative efcacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta‑analysis of randomized controlled trials Xinyang Liao1 · Shi Qiu1 · Yige Bao1 · Wanyu Wang2 · Lu Yang1 · Qiang Wei1 Received: 9 September 2018 / Accepted: 26 November 2018 / Published online: 6 December 2018 © Springer-Verlag GmbH Germany, part of Springer Nature 2018 Abstract Purpose To compare the efcacy and safety profles of diferent phosphodiesterase-5 inhibitors (PDE5Is) administrations for erectile dysfunction (ED) in diabetic men, including on-demand (PRN) and regular regimens (OAD). Materials and methods Searches were carried out in four electronic databases: PubMed (until April 17th, 2017); Scopus (until April 17th, 2017); Embase (until April 17th, 2017); and Cochrane (until April 18th, 2017). The outcomes for this study are as follows: (1) Global Assessment Question (GAQ) positive response rate; (2) changes from baseline to the end of the study in Erectile Function Domain of International Index of Erectile Function (IIEF-EF); and (3) treatment-related adverse events (TRAEs). The comparative efects of PDE5I regimens were analyzed with random-efect models in a Bayes- ian Framework using the GeMTC R package. Results We identifed 1056 records, of which 15 randomized trials with 5274 patients were included. The included stud- ies covered eight kinds of PDE5I administration: avanafl PRN; mirodenafl PRN; sildenafl PRN; tadalafl PRN; tadalafl OAD; udenafl PRN; udenafl OAD; vardenafl PRN; and placebo. In surface under the cumulative ranking curve analysis, vardenafl PRN ranked frst, third and frst, and mirodenafl PRN ranked second, frst and second in GAQ, IIEF-EF, and TRAEs, respectively. Conclusions PDE5I administrations were generally efcient and well-tolerated in diabetic men. Among these administrations, vardenafl PRN and mirodenafl PRN seem to have a possible advantage of efcacy and avoiding adverse efects compared to others. There is no signifcant diference between regular and on-demand regimens of PDE5Is. Keywords Erectile dysfunction · Diabetes · Phosphodiesterase type 5 inhibitors · Network meta-analysis Introduction Xinyang Liao, Shi Qiu and Yige Bao contributed equally as frst authors of this manuscript. Erectile dysfunction (ED) is defned as the persistent inabil- ity to attain and maintain an erection sufcient to permit Electronic supplementary material The online version of this satisfactory sexual performance [1]. A greater risk of ED article (https​://doi.org/10.1007/s0034​5-018-2583-1) contains is strongly associated with diabetes [2]. The prevalence of supplementary material, which is available to authorized users. ED in diabetic men has been reported to be 35–75% [3–7]. * Lu Yang The pathophysiology of ED in diabetic men is multifacto- [email protected] rial, and its main underlying causes fall into three classes: * Qiang Wei psychogenic, neurological, and vasogenic. Psychogenically, [email protected] diabetes-associated depression may decrease libido and 1 reduce the ability to have intercourse [8]. Neurologically, Department of Urology, Institute of Urology, West China diabetes may cause sensory neuropathy, which reduces sex- Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan 610041, People’s Republic of China ual stimulation that triggers the cognitive processes lead- ing to an erection [9]. In the NO/cGMP (nitric oxide/cyclic 2 Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, guanosine monophosphate) signaling pathway of penile People’s Republic of China erection, the cavernosal nerve releases NO in response to Vol.:(0123456789)1 3 1062 World Journal of Urology (2019) 37:1061–1074 sexual stimulation [10]. NO then stimulates the production intracavernous structural alterations due to aging, diabetes, of cGMP via interaction with guanylyl cyclase [11]. cGMP or surgical damage [18, 19]. However, no data are available acts downstream as a second messenger, leading to penile for humans. Tadalafl 2.5 and 5 mg once-daily for ED were erection. Given the reduced NO synthesis and impaired approved by the European Medicines Agency in 2007. As an activity of guanylyl cyclase [12] in diabetic men, it is easier alternative to on-demand regimens, the regular dosing regi- for such patients to experience erectile dysfunction, and mens aforded by PDE5Is allow couples to have spontaneous erectile dysfunction is harder to cure. and more frequent sexual activity because dosing time and Phosphodiesterase-5 inhibitors (PDE5Is), including time of sexual activity do not have to coincide [20]. avanafl, mirodenafl, sildenafl, tadalafl, vardenafl and ude- We aim to compare diferent administrations of PDE5Is nafl are currently the frst-line oral therapy for ED of any and diferent regimens for diabetic ED. Ideally, all PDE5I etiology [13]. The inhibition of PDE5I reduces the hydroly- administrations for diabetic ED should be evaluated via sis of cGMP in the cavernosal tissue, resulting in smooth direct comparisons in high-quality studies, but to date, muscle relaxation with increased arterial blood fow, which no data exist comparing diferent PDE5Is for diabetic ED compresses the subtunical venous plexus, leading to penile directly. A systematic review and network meta-analysis erection [14]. However, in diabetic patients, the decrease (NMA) is one feasible way of combining evidence of direct in NO and impaired activity of guanylyl cyclase restricts and indirect comparisons simultaneously. the production of cGMP. Therefore, PDE5Is might not be as efective for treating diabetic ED as they are for treating non-diabetic ED, as shown by several studies [15]. Evidence acquisition Traditionally, PDE5Is are prescribed as on-demand regimens (PRN) and taken 15–30 min before intercourse. Data source and search strategy Recently, however, some studies showed that the regular regimens (OAD) of PDE5Is yielded higher treatment sat- The study protocol was registered in PROSPERO, isfaction for patients [16, 17]. Further, animal studies have CRD42017062264 (http://www.crd.york.ac.uk/PROSPERO/ shown that PDE5I OAD signifcantly improves or prevents display_recor d.asp?ID=CRD42 01706 2264 ). Searches were Fig. 1 Flowchart of study selec- tion. ED Erectile dysfunction, PDE5Is phosphodiesterase type 5 inhibitors, RCT randomized controlled trial 1 3 World Journal of Urology (2019) 37:1061–1074 1063 Table 1 Estimates of efects (with 95% credible intervals) and confdence ratings for comparisons of PDE5Is for the treatment of erectile dys- function in diabetic men on the outcome Global Assessment Question (GAQ) positive response rate Outcome: GAQ Patients: diabetic men with erectile dysfunction Interventions: mirodenafil PRN, sildenafil PRN, tadalafil PRN, tadalafil OAD, udenafil PRN, udenafil OAD, vardenafil PRN Comparisons: placebo Outcomes: GAQ Comparator #13 RCTs, 2149 patients Mirodenafil Sildenafil Tadalafil Tadalafil Udenafil Udenafil Vardenafil Placebo PRN PRN OAD PRN OAD PRN PRN NA OR 0.61 OR 0.32 OR 0.31 OR 0.62 OR0.45 OR0.91 OR 0.07 Mirodenafil (0.16, 2.2) (0.08, 1.28) (0.07, 1.31) (0.08, 4.86) (0.11, 1.96) (0.21, 3.66) (0.02, 0.23) PRN NA ⨁◯◯◯ ⨁⨁◯◯ ⨁⨁◯◯ ⨁⨁◯◯ ⨁⨁◯◯ ⨁⨁◯◯ ⨁⨁⨁◯ Very low1,2,3 Low2,3 Low2,3 Low2,3 Low2,3 Low2,3 Moderate1 OR 1.64 NA OR 0.52 OR 0.52 OR 1.02 OR 0.75 OR 1.48 OR 0.12 Sildenafil (0.45, 6.15) (0.22, 1.23) (0.21, 1.26) (0.2, 5.82) (0.29, 1.94) (0.62, 3.56) (0.07, 0.19) PRN ⨁◯◯◯ NA ⨁⨁◯◯ ⨁⨁◯◯ ⨁◯◯◯ ⨁⨁◯◯ ⨁⨁◯◯ ⨁⨁⨁◯ Very low1,2,3 Low1,2 Low1,2 Very low1,2,3 Low1,2 Low1,2 Moderate1 Tadalafil OR 3.12 OR 1.92 NA OR 0.99 OR 1.96 OR 1.43 OR 2.83 OR 0.22 OAD (0.78, 13.2) (0.81, 4.51) (0.36, 2.8) (0.35, 12.07) (0.49, 4.23) (1.04, 7.81) (0.11, 0.45) ⨁⨁⨁◯ ⨁⨁◯◯ NA ⨁⨁⨁◯ ⨁⨁◯◯ ⨁⨁⨁◯ ⨁⨁⨁◯ ⨁⨁⨁◯ Moderate1 Low1,2 Moderate2 Low2,3 Moderate2 Moderate2 Moderate2 OR 3.19 OR 1.93 OR 1.01 NA OR 1.96 OR 1.45 OR 2.86 OR 0.22 Tadalafil (0.76, 13.5) (0.79, 4.71) (0.36, 2.82) (0.34, 12.24) (0.48, 4.4) (1, 8.14) (0.1, 0.47) PRN ⨁⨁◯◯ ⨁⨁◯◯ ⨁⨁⨁◯ NA ⨁⨁◯◯ ⨁⨁⨁◯ ⨁⨁⨁◯ ⨁⨁⨁⨁ Low2,3 Low1,2 Moderate2 Low2,3 Moderate2 Moderate2 High OR 1.62 OR 0.98 OR 0.51 OR 0.51 NA OR 0.73 OR 1.45 OR 0.11 Udenafil (0.21, 11.93) (0.17, 5.11) (0.08, 2.86) (0.08, 2.91) (0.18, 2.84) (0.23, 8.12) (0.02, 0.54) OAD ⨁⨁◯◯ ⨁◯◯◯ ⨁⨁◯◯ ⨁⨁◯◯ NA ⨁⨁⨁◯ ⨁⨁◯◯ ⨁⨁⨁◯ Low2,3 Very low1,2,3 Low2,3 Low2,3 Moderate3 Low2,3 Moderate3 OR 2.2 OR 1.34 OR 0.7 OR 0.69 OR 1.36 NA OR 1.98 OR 0.15 Udenafil (0.51, 9.51) (0.51, 3.43) (0.24, 2.02) (0.23, 2.08) (0.35, 5.71) (0.67, 5.79) (0.07, 0.34) PRN ⨁⨁◯◯ ⨁⨁◯◯ ⨁⨁⨁◯ ⨁⨁⨁◯ ⨁⨁⨁◯ NA ⨁⨁⨁◯ ⨁⨁⨁⨁ Low2,3 Low1,2 Moderate2 Moderate2 Moderate3 Moderate2 High OR 1.1 OR 0.67 OR 0.35 OR 0.35 OR 0.69 OR 0.5 NA OR 0.08 Vardenafil (0.27, 4.67) (0.28, 1.62) (0.13, 0.96) (0.12, 1) (0.12, 4.27) (0.17, 1.49) (0.04, 0.16) PRN ⨁⨁⨁◯ ⨁⨁◯◯ ⨁⨁⨁◯ ⨁⨁⨁◯ ⨁⨁⨁◯ ⨁⨁⨁◯ NA ⨁⨁⨁⨁ Moderate3 Low1,2 Moderate2 Moderate2 Moderate3 Moderate2 High OR 14.22 OR 8.66 OR 4.53 OR 4.48 OR 8.86 OR 6.47 OR 12.86 NA (4.32, 49.26) (5.37, 14.12) (2.24, 9.25) (2.12, 9.63) (1.85, 46.86) (2.93, 14.74) (6.27, 26.49) Placebo ⨁⨁⨁◯ ⨁⨁⨁◯ ⨁⨁⨁⨁ ⨁⨁⨁⨁ ⨁⨁⨁◯ ⨁⨁⨁⨁ ⨁⨁⨁⨁ NA Moderate3 Moderate1 High High Moderate3 High High GRADE Working Group grades of evidence—high quality: further research is very unlikely to change our confdence in the estimate of efect; moderate quality: further research is likely to have an important impact on our confdence in the estimate of efect and may change the estimate; low quality: further research is very likely to have
Recommended publications
  • WO 2017/048702 Al

    WO 2017/048702 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/048702 A l 2 3 March 2017 (23.03.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 487/04 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/519 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/05 1490 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 13 September 2016 (13.09.201 6) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/218,493 14 September 2015 (14.09.2015) US (84) Designated States (unless otherwise indicated, for every 62/218,486 14 September 2015 (14.09.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: INFINITY PHARMACEUTICALS, INC.
  • Phosphodiesterase-5 Inhibitors and the Heart: Heart: First Published As 10.1136/Heartjnl-2017-312865 on 8 March 2018

    Phosphodiesterase-5 Inhibitors and the Heart: Heart: First Published As 10.1136/Heartjnl-2017-312865 on 8 March 2018

    Heart Online First, published on March 8, 2018 as 10.1136/heartjnl-2017-312865 Review Phosphodiesterase-5 inhibitors and the heart: Heart: first published as 10.1136/heartjnl-2017-312865 on 8 March 2018. Downloaded from compound cardioprotection? David Charles Hutchings, Simon George Anderson, Jessica L Caldwell, Andrew W Trafford Unit of Cardiac Physiology, ABSTRACT recently reported that PDE5i use in patients with Division of Cardiovascular Novel cardioprotective agents are needed in both type 2 diabetes (T2DM) and high cardiovascular Sciences, School of Medical risk was associated with reduced mortality.6 The Sciences, Faculty of Biology, heart failure (HF) and myocardial infarction. Increasing Medicine and Health, The evidence from cellular studies and animal models effect was stronger in patients with prior MI and University of Manchester, indicate protective effects of phosphodiesterase-5 was associated with reduced incidence of new MI, Manchester Academic Health (PDE5) inhibitors, drugs usually reserved as treatments of raising the possibility that PDE5is could prevent Science Centre, Manchester, UK erectile dysfunction and pulmonary arterial hypertension. both complications post-MI and future cardio- PDE5 inhibitors have been shown to improve vascular events. Subsequent similar findings were Correspondence to observed in a post-MI cohort showing PDE5i use Dr David Charles Hutchings, contractile function in systolic HF, regress left ventricular Institute of Cardiovascular hypertrophy, reduce myocardial infarct size and suppress was accompanied with reduced mortality and HF 7 Sciences, The University of ischaemia-induced ventricular arrhythmias. Underpinning hospitalisation. Potential for confounding in these Manchester, Manchester, M13 these actions are complex but increasingly understood observational studies is high, however, and data 9NT, UK; david.
  • Tainted Products Marketed As Dietary Supplements

    Tainted Products Marketed As Dietary Supplements

    Tainted Products Marketed as Dietary Supplements Jason Humbert, MPS Nicole Kornspan, MPH Regulatory Operations Officer Consumer Safety Officer Food and Drug Administration Office of Regulatory Affairs Health Fraud Branch Overview • Definition of health fraud • Tainted products – then and now • Dietary Supplement Health and Education Act of 1994 (DSHEA) • Concerns related to tainted products • Enforcement challenges • Resources 2 FDA Definition of Health Fraud • The deceptive promotion, advertisement, or sale of products as being effective to diagnose, prevent, cure, treat, or mitigate disease, or to provide a beneficial effect on health, but which have not been scientifically proven safe and effective for such purposes. • May be deliberate, or done without adequate knowledge or understanding of the product. 3 Health Fraud: What are the Risks? • Direct health hazard: product is likely to cause injury, death or other serious adverse effect when used as directed • Indirect health hazard: product poses no direct hazard, but consumer is likely to delay or discontinue appropriate medical treatment by relying on product. 4 4 Tainted Products – Then • 1865-1906: “Golden age” of American quackery • 1905 estimate: 50,000 patent medicines – Drugs were bought and sold like any other consumer good. – Contain dangerous, addictive, misidentified ingredients – Alcohol, cocaine, heroin, opium, without restrictions – Did not have to disclose ingredients – No warnings about misuse – Manufacturer not listed 5 Tainted Products – Now 6 6 Dietary Supplement
  • Screening of Phosphodiesterase-5 Inhibitors and Their Analogs in Dietary Supplements by Liquid Chromatography–Hybrid Ion Trap–Time of Flight Mass Spectrometry

    Screening of Phosphodiesterase-5 Inhibitors and Their Analogs in Dietary Supplements by Liquid Chromatography–Hybrid Ion Trap–Time of Flight Mass Spectrometry

    molecules Article Screening of Phosphodiesterase-5 Inhibitors and Their Analogs in Dietary Supplements by Liquid Chromatography–Hybrid Ion Trap–Time of Flight Mass Spectrometry 1,2, 1,3, 4 5 3 Unyong Kim y, Hyun-Deok Cho y, Myung Hee Kang , Joon Hyuk Suh , Han Young Eom , Junghyun Kim 6, Sumin Seo 1, Gunwoo Kim 1, Hye Ryoung Koo 1, Nary Ha 1, Un Tak Song 1 and Sang Beom Han 1,* 1 Department of Pharmaceutical Analysis, College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, Korea; [email protected] (U.K.); [email protected] (H.-D.C.); [email protected] (S.S.); [email protected] (G.K.); [email protected] (H.R.K); [email protected] (N.H.); [email protected] (U.T.S.) 2 Biocomplete Co., Ltd., 272 Digital-ro, Guro-gu, Seoul 08389, Korea 3 Bioanalysis and Pharmacokinetics Study Group, Korea Institute of Toxicology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, Korea; [email protected] 4 Agro-Livestock and Fishery Products Division, Busan Regional Korea Food and Drug Administration, 222 Geoje-daero, Yunje-gu, Busan 47537, Korea; [email protected] 5 Department of Food Science and Human Nutrition, Citrus Research and Education Center, University of Florida, 700 Experiment Station Rd, Lake Alfred, FL 33850, USA; joonhyuksuh@ufl.edu 6 Forensic Toxicology Division, National Forensic Service, 10 Ipchoon-ro, Wonju, Gangwon-do 26460, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-2-820-5596 These authors contributed equally to this work. y Received: 22 May 2020; Accepted: 9 June 2020; Published: 12 June 2020 Abstract: An accurate and reliable method based on ion trap–time of flight mass spectrometry (IT–TOF MS) was developed for screening phosphodiesterase-5 inhibitors, including sildenafil, vardenafil, and tadalafil, and their analogs in dietary supplements.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Penile Injection Therapy | Memorial Sloan Kettering Cancer Center

    Penile Injection Therapy | Memorial Sloan Kettering Cancer Center

    PATIENT & CAREGIVER EDUCATION Penile Injection Therapy This information will help you learn to inject medication into your penis. This is called penile injection therapy. Penile injections can help you achieve an erection if you have erectile dysfunction (ED). Read this resource carefully before starting injection therapy. If you do not follow the instructions in this resource, your doctor or APP may stop prescribing your penile injection medications and supplies. About Penile Injection Therapy The tissue that causes you to get an erection (erectile tissue) is a muscle. Going long periods of time without an erection is unhealthy for erectile tissue and may damage it. We believe having erections keeps erectile tissue healthy. A penile injection helps you have an erection. It works best if it’s given about 5 to 15 minutes before you want an erection. Penile Injection Therapy 1/19 Giving Yourself the Injection Your advanced practice provider (APP) will review the instructions below with you. Generally, the training for the injections takes 2 office visits. Please be aware that each visit may take up to 1 hour, so you should plan your schedule on the day of your appointment. Use this resource to help you the first few times you inject on your own. Do not take the following medications within 18 hours of injecting (before or after): Sildenafil (Viagra®) - 20 mg to 100 mg Vardenafil (Levitra®) - 10 mg to 20 mg Avanafil (Stendra®) - 50 mg to 200 mg If you take tadalafil (Cialis®) 10 mg or 20 mg, do not inject within 72 hours (3 days) of taking the medication.
  • Call for Methods

    Call for Methods

    CALL FOR METHODS Methods for Identification, Determination, or Screening Methods for PDE5 Inhibitors AOAC INTERNATIONAL invites method developers to submit methods for consideration and possible evaluation through the AOAC Official MethodsSM program. Prospective methods may be qualitative, identification methods, and/or screening methods for phosphodiesterase type 5 inhibitors (PDE5 inhibitors) in dietary ingredients and supplements. OBJECTIVE: The objective of this call for methods is to select and evaluate methods that can be used for routine surveillance of dietary ingredients. Acceptable methods must be reliable and reproducible when used by trained analysts in accredited laboratories. Interested method developers should provide a description of their proposed method and data characterizing the analytical performance of the proposed method. For the purpose of this Call-for-Methods, PDE5 inhibitors are defined as avanafil, lodenafil carbonate, mirodenafil, sildenafill, tadalafil, udenafil, or vardenafil; or any of their analogs. Any analytical technique that measures the analytes of interest and meets the method performance requirements specified in the SMPR will be considered. It is acceptable to have a different analytical method for each class of analytes. Applicable SMPRs: • View AOAC 2014.010 – Methods for the Identification of PDE5 Inhibitors • View AOAC SMPR 2014.011 – Methods for the Determination of PDE5 Inhibitors • View AOAC SMPR 2014.012 – Screening Methods for PDE5 Inhibitors Submit Your Method AOAC INTERNATIONAL METHOD SUBMISSION PROCESS: AOAC invites method authors to submit their methods with no fee required. Interested method authors or developers should provide a copy of their proposed method, as well as any available data characterizing the analytical performance and scientific validity of the method in AOAC format.
  • 2251 Adulteration of Dietary Supplements with Drugs

    2251 Adulteration of Dietary Supplements with Drugs

    BRIEFING 2251 Adulteration of Dietary Supplements with Drugs and Drug Analogs. This new general chapter provides tools for detection of dietary supplement adulteration with ⟨extraneously⟩ added synthetic compounds. The illegal addition of synthetic substances to products marketed as dietary supplements constitutes a significant threat to consumer health, considering that these products, administered without medical supervision, may contain toxic constituents or substances whose safety has never been examined, and whose interaction with medications may be unpredictable or lethal. The proposed chapter suggests multiple methods for detection of adulteration. It is advisable to use several screening techniques to maximize the potential for adulteration detection, because no single methodology is universally applicable. Presently, the chapter targets supplements adulterated with phosphodiesterase type 5 inhibitors; subsequent revisions will include methodologies specific to analysis of adulterated weight loss and sports performance enhancement products. It is anticipated that this chapter will be updated regularly. (GCCA: A. Bzhelyansky.) Correspondence Number—C144928 Add the following: ▪ 2251 ADULTERATION OF DIETARY SUPPLEMENTS WITH DRUGS AND DRUG ANALOGS ⟨ ⟩ INTRODUCTION The illegal addition of undeclared synthetic compounds to products marketed as dietary supplements1 (DS) is a serious problem. This fraud is practiced to impart therapeutic effects that cannot be achieved by the supplement constituents alone. Increasingly, synthetic intermediates and structural analogs of the pharmaceuticals and drugs that have been discontinued or withdrawn from the market due to unsatisfactory safety profiles are being used as adulterants. Multiple adulterating compounds may be added to a single DS, frequently in erratic amounts. The proposed test methodologies facilitate screening of DS for synthetic adulterants. No individual technique is capable of addressing all potential analytes; thus, a combination of orthogonal approaches adds certainty to the analytical outcome.
  • Vardenafil Better Choice for Premature Ejaculation

    Vardenafil Better Choice for Premature Ejaculation

    August 15, 2005 • www.familypracticenews.com Men’s Health 47 Vardenafil Better Choice for Premature Ejaculation BY ROBERT FINN (24%) of the men and was secondary (in On a self-rating scale of 0-8, where 0 Center but is now at the University of San Francisco Bureau most cases to erectile dysfunction) in the means PE almost never, 4 means PE about Hamburg. remaining 26 men (77%). half the time, and 8 means PE almost al- Self-ratings of sexual satisfaction, on a 0- S AN A NTONIO — Vardenafil improved After a 4-week run-in period, 17 men ways, the mean score was 6.14 at baseline, 5 scale, where 0 means not at all satisfied premature ejaculation more than sertra- were given 10-mg vardenafil 10 minutes 4.28 with sertraline, and 3.2 with varde- and 5 means extremely satisfied, averaged line, Frank Sommer, M.D., reported at the before intercourse for 6 weeks. The other nafil. 1.4 at baseline, 3.2 with sertraline, and 4.2 annual meeting of the American Urolog- 17 received 50 mg of sertraline 4 hours be- IVELT, as measured by a stopwatch, with vardenafil. In addition, the partners’ ical Association. fore intercourse. averaged 0.54 minutes at baseline, 2.87 sexual satisfaction showed significant in- Both vardenafil (Levitra), a phosphodi- After a 1-week washout period, the men minutes with sertraline, and 5.23 minutes creases for sertraline and even more so for esterase-5 inhibitor, and sertraline (Zoloft), who had been receiving sertraline with vardenafil, reported Dr. Sommer, vardenafil.
  • Wo 2010/075090 A2

    Wo 2010/075090 A2

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
  • Repurposing Erectile Dysfunction Drugs Tadalafil and Vardenafil to Increase Bone Mass

    Repurposing Erectile Dysfunction Drugs Tadalafil and Vardenafil to Increase Bone Mass

    Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone mass Se-Min Kima,b,1, Charit Tanejaa,b, Helena Perez-Penac, Vitaly Ryua,b, Anisa Gumerovaa,b, Wenliang Lic, Naseer Ahmada,b, Ling-Ling Zhua,b, Peng Liua,b, Mehr Mathewa,b, Funda Korkmaza,b, Sakshi Geraa,b, Damini Santa,b, Elina Hadeliaa,b, Kseniia Ievlevaa,b,d, Tan-Chun Kuoa,b, Hirotaka Miyashitaa,b, Li Liue,f, Irina Tourkovae,f, Sarah Stanleyb, Daria Liznevaa,b, Jameel Iqbala,b, Li Suna,b, Ronald Tamlerb, Harry C. Blaire,f, Maria I. Newa,g,1, Shozeb Haiderc, Tony Yuena,b,2, and Mone Zaidia,b,2 aThe Mount Sinai Bone Program, Icahn School of Medicine at Mount Sinai, New York, NY 10029; bDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029; cDepartment of Pharmaceutical and Biological Chemistry, University College London School of Pharmacy, WC1N 1AX London, United Kingdom; dDepartment of Reproductive Health, Scientific Center for Family Health and Human Reproduction Problems, 664003 Irkutsk, Russian Federation; eDepartment of Pathology, Pittsburgh Veterans Affairs Healthcare System, Pittsburgh, PA 15240; fDepartment of Pathology, University of Pittsburgh, Pittsburgh, PA 15261; and gDepartment of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029 Contributed by Maria I. New, April 17, 2020 (sent for review January 27, 2020; reviewed by Yousef Abu-Amer, Fayez F. Safadi, and Mei Wan) We report that two widely-used drugs for erectile dysfunction, bone mass, respectively (18, 19). Likewise, soluble guanylate cy- tadalafil and vardenafil, trigger bone gain in mice through a com- clase has also been targeted for bone gain (20, 21).
  • Gastroesophageal Reflux Disease (GERD)

    Gastroesophageal Reflux Disease (GERD)

    Guidelines for Clinical Care Quality Department Ambulatory GERD Gastroesophageal Reflux Disease (GERD) Guideline Team Team Leader Patient population: Adults Joel J Heidelbaugh, MD Objective: To implement a cost-effective and evidence-based strategy for the diagnosis and Family Medicine treatment of gastroesophageal reflux disease (GERD). Team Members Key Points: R Van Harrison, PhD Diagnosis Learning Health Sciences Mark A McQuillan, MD History. If classic symptoms of heartburn and acid regurgitation dominate a patient’s history, then General Medicine they can help establish the diagnosis of GERD with sufficiently high specificity, although sensitivity Timothy T Nostrant, MD remains low compared to 24-hour pH monitoring. The presence of atypical symptoms (Table 1), Gastroenterology although common, cannot sufficiently support the clinical diagnosis of GERD [B*]. Testing. No gold standard exists for the diagnosis of GERD [A*]. Although 24-hour pH monitoring Initial Release is accepted as the standard with a sensitivity of 85% and specificity of 95%, false positives and false March 2002 negatives still exist [II B*]. Endoscopy lacks sensitivity in determining pathologic reflux but can Most Recent Major Update identify complications (eg, strictures, erosive esophagitis, Barrett’s esophagus) [I A]. Barium May 2012 radiography has limited usefulness in the diagnosis of GERD and is not recommended [III B*]. Content Reviewed Therapeutic trial. An empiric trial of anti-secretory therapy can identify patients with GERD who March 2018 lack alarm or warning symptoms (Table 2) [I A*] and may be helpful in the evaluation of those with atypical manifestations of GERD, specifically non-cardiac chest pain [II B*]. Treatment Ambulatory Clinical Lifestyle modifications.